Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 8/20 | 0.49 |
| ▸ | HMGCR | P04035 | 2/20 | 0.42 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.42 |
| ▸ | CDC25A | P30304 | 5/20 | 0.41 |
| ▸ | CDC25B | P30305 | 5/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | OSBP | P22059 | 1/20 | 0.41 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.41 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.41 |
| ▸ | GPR183 | P32249 | 1/20 | 0.39 |
| ▸ | RORA | P35398 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3229562 | 0.83 | EBP (0.48) | EBPHMGCRNPC1L1CDC25ACDC25B | |
| SCHEMBL11046219 | 0.79 | EBP (0.48) | EBPNPC1L1CDC25ACDC25B | |
| SCHEMBL11046212 | 0.79 | EBP (0.48) | EBPNPC1L1CDC25ACDC25B | |
| SCHEMBL11046214 | 0.79 | EBP (0.48) | EBPNPC1L1CDC25ACDC25B | |
| SCHEMBL1470722 | 0.77 | EBP (0.48) | EBPHMGCRNPC1L1CDC25ACDC25B | |
| SCHEMBL1470719 | 0.77 | EBP (0.48) | EBPHMGCRNPC1L1CDC25ACDC25B | |
| SCHEMBL1470720 | 0.77 | EBP (0.48) | EBPHMGCRNPC1L1CDC25ACDC25B | |
| SCHEMBL332666 | 0.77 | CDC25A (0.51) | EBPNPC1L1CDC25ACDC25BUSP2 | |
| SCHEMBL29410405 | 0.77 | CDC25A (0.51) | EBPNPC1L1CDC25ACDC25BUSP2 | |
| SCHEMBL29398347 | 0.77 | CDC25A (0.51) | EBPNPC1L1CDC25ACDC25BUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043677-A1 | INHALABLE THERAPEUTICS | OREGON STATE UNIVERSITY (US) | 2023-02-09 | — | — | US | claimed |
| WO-2023002509-A1 | LIPID FORMULATION FOR DELIVERY OF THERAPEUTIC AGENTS | INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE (IN) | 2023-01-26 | — | — | WO | claimed |
| US-20200129445-A1 | LIPID NANOPARTICLE FORMULATION | ARES CAPITAL CORPORATION, AS AGENT | 2020-04-30 | — | — | US | claimed |
| WO-2018170336-A1 | LIPID NANOPARTICLE FORMULATION | MODERNATX, INC. (US) | 2018-09-20 | — | — | WO | claimed |
| CN-108472303-A | composition for treating cataract | 卡塔科雷公司 | 2018-08-31 | — | — | CN | claimed |
| CN-108024957-A | Compositions and methods for nanoparticle lyophilisate form | 日东电工株式会社 | 2018-05-11 | — | — | CN | claimed |
| CN-105017367-B | A kind of method separating lanosterol and lanostenol | 浙江花园生物高科股份有限公司 | 2016-08-24 | — | — | CN | claimed |
| CN-105017367-A | Method for separating lanosterol and lanostenol | ZHEJIANG GARDEN BIOCHEMICAL HIGH TECH CO LTD | 2015-11-04 | — | — | CN | claimed |
| CN-104672311-A | Lipopeptides for delivery of nucleic acids | MARINA BIOTECH INC | 2015-06-03 | — | — | CN | claimed |
| CN-101939027-B | Lipopeptides for delivery of nucleic acids | MDRNA INC | 2014-07-30 | — | — | CN | claimed |
| CN-101198309-A | Composition for protection of body surface | ASAHI CHEMICAL CORP (JP) | 2008-06-11 | — | — | CN | claimed |
| CN-1153564-C | Antiperspirant deodorant compositions | ����ϲ�� | 2004-06-16 | — | — | CN | claimed |
| CN-1487956-A | A catalyst compositio and method for its preparation and use in a polymerization process | �������ٶ������������ι�˾ | 2004-04-07 | — | — | CN | claimed |
| CN-1069838-C | Stable microbubble suspensions as enhancement agents for ultrasound echography | POLERKO INTERNAT S A (NL) | 2001-08-22 | — | — | CN | claimed |
| CN-1202816-A | Antiperspirant deodorant compositions | HELENS CURTIS INC (US) | 1998-12-23 | — | — | CN | claimed |
| CN-1088456-A | Stable microbubble suspensions as enhancement agents for ultrasound echography | SINT SA (CH) | 1994-06-29 | — | — | CN | claimed |
| EP-0461108-B1 | PARTIALLY FUSED PEPTIDE PELLET | ENDOCON INC (US) | 1994-06-01 | — | — | EP | claimed |
| US-4748161-A | Triterpenyl esters of organic acids and hypolipidemic agents composed of them | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1988-05-31 | — | — | US | claimed |
| CN-85109752-A | Preparation triterpenoid organic acid ester and the method that contains the hypolipidemic agents of this compounds | — | 1986-12-17 | — | — | CN | claimed |
| EP-0166542-A2 | Triterpenyl esters of organic acids, process for their production, and hypolipidemic agents composed of them | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1986-01-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043677-A1 | INHALABLE THERAPEUTICS | RNMT, CETP, NPC1L1 | EBP 1179/4885HMGCR 112/4885NPC1L1 3/4885 |
| US-20200129445-A1 | LIPID NANOPARTICLE FORMULATION | TTPA, SREBF1, SREBF2 | EBP 121/4885HMGCR 218/4885NPC1L1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.